• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Esperion Theraptc (NQ: ESPR )

    2.720 -0.150 (-5.23%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 4,484,813
    Open 2.900
    Bid (Size) 2.720 (3)
    Ask (Size) 2.740 (50)
    Prev. Close 2.870
    Today's Range 2.710 - 2.930
    52wk Range 0.7000 - 3.400
    Shares Outstanding 28,277,493
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget
    Since wealth without health is utterly meaningless, investors may have some confidence with these biotech stocks to buy. 
    Via InvestorPlace
    3 Penny Stocks to Buy if You Want to Spend Less and Earn More
    These penny stocks to buy provide a good opportunity for investors to buy low-priced stocks that provide significant growth potential. 
    Via InvestorPlace

    Performance

    YTD
    -6.85%
    -6.85%
    1 Month
    +9.68%
    +9.68%
    3 Month
    +30.77%
    +30.77%
    6 Month
    +16.24%
    +16.24%
    1 Year
    +77.78%
    +77.78%

    More News

    Read More
    Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Argan Reports Strong Earnings, Joins Geron, Planet Labs PBC And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    Esperion to Participate in Upcoming June Investor Conferences
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    Esperion Therapeutics/Otsuka Partnered Cholesterol Drug Shows Effective In Japan Study
    Via Benzinga
    Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    Investor Spotlight: Companies Poised for Growth Amid Recent Developments: VTAK, ESPR, FGEN, GSUN, INBS
    Via AB Newswire
    ESPR Stock Earnings: Esperion Therapeutics Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars
    Via Benzinga
    Exposures Product Safety
    Why Is AgriFORCE Growing (AGRI) Stock Down 31% Today?
    Via InvestorPlace
    Why Is GreenPower Motor (GP) Stock Down 36% Today?
    Via InvestorPlace
    Why Is Esperion Therapeutics (ESPR) Stock Up 13% Today?
    Via InvestorPlace
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Via InvestorPlace
    Esperion Reports First Quarter 2024 Financial Results
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    Esperion to Participate in Upcoming May Investor Conferences
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    Esperion to Report First Quarter 2024 Financial Results on May 7
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    Applied Digital Reports Downbeat Results, Joins Nurix Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Why Esperion Therapeutics Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.